rPA 102
Alternative Names: Anthrax vaccine recombinant - Emergent Biosolutions; PreviThrax; Recombinant protective antigen anthrax vaccine, purified; rPA anthrax vaccine - Emergent BioSolutionsLatest Information Update: 22 Jul 2015
Price :
$50 *
At a glance
- Originator United States Army Medical Research Institute of Infectious Diseases
- Developer Emergent BioSolutions
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Anthrax
Most Recent Events
- 22 Jul 2015 Phase-II development is ongoing in the US
- 04 Oct 2012 The Biomedical Advanced Research Development Authority exercises contract option to further advance the development of rPA anthrax vaccine
- 18 Sep 2010 Emergent BioSolutions signs contract with the Biomedical Advanced Research and Development Authority for the development of a rPA anthrax vaccine